Compare MDB & UTHR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MDB | UTHR |
|---|---|---|
| Founded | 2007 | 1996 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 30.0B | 25.1B |
| IPO Year | 2017 | 1999 |
| Metric | MDB | UTHR |
|---|---|---|
| Price | $264.83 | $572.31 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 34 | 14 |
| Target Price | $368.67 | ★ $567.57 |
| AVG Volume (30 Days) | ★ 1.5M | 570.3K |
| Earning Date | 06-03-2026 | 04-29-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 49.13 | 13.07 |
| EPS | N/A | ★ 27.86 |
| Revenue | N/A | ★ $1,483,300,000.00 |
| Revenue This Year | $18.88 | $7.08 |
| Revenue Next Year | $17.14 | $14.32 |
| P/E Ratio | ★ N/A | $21.12 |
| Revenue Growth | N/A | ★ 2.38 |
| 52 Week Low | $149.01 | $272.18 |
| 52 Week High | $444.72 | $607.89 |
| Indicator | MDB | UTHR |
|---|---|---|
| Relative Strength Index (RSI) | 53.07 | 56.34 |
| Support Level | $256.65 | $464.92 |
| Resistance Level | $266.50 | $607.89 |
| Average True Range (ATR) | 13.23 | 16.71 |
| MACD | 5.25 | -1.17 |
| Stochastic Oscillator | 91.25 | 44.07 |
Founded in 2007, MongoDB is a vendor of a document-oriented database that accelerates development processes of new applications. Enterprise customers can choose between the fully managed offering, MongoDB Atlas, or the self-managed version, MongoDB Enterprise Advanced. MongoDB is a popular tool among developers, and its free Community Server has recorded over 500 million downloads since 2009.
United Therapeutics Corp specializes in drug development for pulmonary arterial hypertension (PAH), a rare and progressive disease marked by abnormally high blood pressure in the arteries of the lungs. The company's therapies for PAH largely focus on the prostacyclin pathway, and many of its treatments are based on the same molecule, treprostinil. The company markets and sells the following commercial therapies in the United States to treat PAH: Tyvaso DPI (treprostinil) Inhalation Powder, Remodulin Injection, Orenitram (treprostinil) Extended-Release Tablets, Adcirca (tadalafil) Tablets, and Unituxin. It derives maximum revenue from the sale of Tyvaso DPI. Geographically, the company operates in United States and Rest of the World, of which United States generates majority of the revenue.